AKT1 and Hepatic fibrosis: We hypothesized that AKT/mTOR signaling pathway was activated in the pathophysiological onset of early cirrhotic portal hypertension, and rapamycin treatment would have multiple mechanisms of action against hepatic fibrosis and portal hypertension progression.